and detection of complex
genetic changes
Products + Services
Unidirectional dGH probes
Targeted tracking of transgenes as small as 2kb
Insertional copy number and distribution in heterogeneous cell populations
Detects structural variations in off target effects of CRISPR/Cas9
Unidirectional dGH probes
Unbiased, whole-genome assessment of all structural rearrangements
10x improvement in resolution over G-banding
3x the relative signal and resolution compared to BAC FISH
Repeat free
Detect targets as small as 2kb
Traditional G-banding and karyotyping analysis
Gold standard structural rearrangement detection
Applications
Cellular Engineering
Monitoring Cellular Engineering Outcomes
On/Off Target Effects
Orthogonal Data for Sequencing
Variant Discovery
Genomic Stability Assessment
Radiation Biodosimetry
directional Genome Hybridization (dGH)
Structural Rearrangements
Inversions
Translocations
KromaTiD News
Press Releases & Company News
- KromaTiD Announces EARLY ACCESS Launch of TP53/CEP17 Kit for Synthetic Oligonucleotide-Based FISH Assay
- KromaTiD Announces Launch of dGH SCREEN™
- Applied Spectral Imaging and KromaTiD announce strategic commercial partnership
- KromaTiD and dGH in-Site featured in Genetic Engineering & Biotechnology News
Videos, Presentations & Webinars
- KromaTiD: Who We Are
- What is directional Genome Hybridization (dGH)?
- KromaTiD’s Cell Culture Services Protocol
- Dr. Chris Tompkins and Erin Cross present webinar for the launch of dGH SCREEN™ for unbiased whole genome analysis of chromosomal structural rearrangements
- Dr. Lauren Kinner-Bibeau presents webinar on single-cell measurements of genomic inserts and transgenes
- KromaTiD presents at the 2020 virtual NextGen Omics Series
- KromaTiD CTO Dr. Chris Tompkins presents at the 2020 Cell & Gene Therapy Virtual Congress
Market News
- Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next Gen Allogenic T-Cell Therapy for Auto-Immune Disease
- Locus Biosceinces – Triangle Gene Editing CEO revolution in Life Sciences happening in the Triangle
- Bluebird Bio hits FDA clinical trial HOLD for gene therapy in Sickle Cell disease
- Regulating Gene-Editing Technology
- Study encourages cautious approach using CRISPR therapeutics
- Bay Area Biotech is Taking Gene Therapy to the Next Level with Chemogenomics
- CRISPR-Editing Biotech Arbor Bio adds $215M for Liver, CNS Diseases Therapies
- A Gene-Editing Experiment Let These Patients With Vision Loss See Color Again
- Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
- A CRISPR gene-editing breakthrough stops life-threatening disease in Intellia-sponsored study